CN104822392B - 抑制活化的t‑细胞中il‑22表达的方法 - Google Patents

抑制活化的t‑细胞中il‑22表达的方法 Download PDF

Info

Publication number
CN104822392B
CN104822392B CN201380062076.0A CN201380062076A CN104822392B CN 104822392 B CN104822392 B CN 104822392B CN 201380062076 A CN201380062076 A CN 201380062076A CN 104822392 B CN104822392 B CN 104822392B
Authority
CN
China
Prior art keywords
amount
vitamin
composition
cells
pde4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380062076.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN104822392A (zh
Inventor
P·洛瓦托
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leo Pharma AS
Original Assignee
Leo Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma AS filed Critical Leo Pharma AS
Publication of CN104822392A publication Critical patent/CN104822392A/zh
Application granted granted Critical
Publication of CN104822392B publication Critical patent/CN104822392B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380062076.0A 2012-11-30 2013-11-28 抑制活化的t‑细胞中il‑22表达的方法 Expired - Fee Related CN104822392B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261731867P 2012-11-30 2012-11-30
US61/731,867 2012-11-30
PCT/EP2013/074958 WO2014083099A1 (en) 2012-11-30 2013-11-28 A method of inhibiting the expression of il-22 in activated t-cells

Publications (2)

Publication Number Publication Date
CN104822392A CN104822392A (zh) 2015-08-05
CN104822392B true CN104822392B (zh) 2017-09-08

Family

ID=49681024

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380062076.0A Expired - Fee Related CN104822392B (zh) 2012-11-30 2013-11-28 抑制活化的t‑细胞中il‑22表达的方法

Country Status (6)

Country Link
US (1) US9855285B2 (enExample)
EP (1) EP2925364A1 (enExample)
JP (1) JP6367819B2 (enExample)
CN (1) CN104822392B (enExample)
RU (1) RU2663448C2 (enExample)
WO (1) WO2014083099A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201701583D0 (en) * 2017-01-31 2017-03-15 Drug Delivery Solutions Ltd Topical composition
FR3071508B1 (fr) * 2017-09-26 2022-07-29 Genoskin Modele ex vivo de peau humaine inflammee et ses utilisations pour le criblage de composes anti-inflammatoires
EP3853204A4 (en) * 2018-09-21 2022-06-22 Apramitha Innovations Private Limited IMPROVED AND STABLE APREMILAST PHARMACEUTICAL COMPOSITIONS
JP2022518292A (ja) * 2019-01-23 2022-03-14 パス セラピューティクス，インク． ホスホジエステラーゼ４（ｐｄｅ４）阻害によるてんかんの治療方法
US20210212962A1 (en) * 2020-01-13 2021-07-15 Sol-Gel Technologies Ltd. Methods and compositions for the treatment of granuloma annulare or subcutaneous inflammation and non-infection granulomatous diseases
CN116919958A (zh) * 2023-07-05 2023-10-24 南方医科大学口腔医院 罗氟司特在骨缺损修复治疗中的应用
WO2025221488A1 (en) * 2024-04-16 2025-10-23 Alto Neuroscience, Inc. Transdermal administration of pde4 inhibitors for reduction in adverse events

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008077404A1 (en) * 2006-12-22 2008-07-03 Leo Pharma A/S Substituted acetophenones useful as pde4 inhibitors
WO2008104175A2 (en) * 2007-02-28 2008-09-04 Leo Pharma A/S Novel phosphodiesterase inhibitors
WO2008128538A1 (en) * 2007-04-19 2008-10-30 Leo Pharma A/S Src family kinase inhibitors
WO2010069322A1 (en) * 2008-12-19 2010-06-24 Leo Pharma A/S Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases
CN102781425A (zh) * 2009-12-22 2012-11-14 利奥制药有限公司 含有维生素d类似物以及溶剂和表面活性剂混合物的皮肤用组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006123726A1 (ja) * 2005-05-18 2006-11-23 Kyowa Hakko Kogyo Co., Ltd. 医薬組成物
NZ603895A (en) * 2010-06-24 2014-10-31 Leo Pharma As Novel phosphodiesterase inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008077404A1 (en) * 2006-12-22 2008-07-03 Leo Pharma A/S Substituted acetophenones useful as pde4 inhibitors
WO2008104175A2 (en) * 2007-02-28 2008-09-04 Leo Pharma A/S Novel phosphodiesterase inhibitors
WO2008128538A1 (en) * 2007-04-19 2008-10-30 Leo Pharma A/S Src family kinase inhibitors
WO2010069322A1 (en) * 2008-12-19 2010-06-24 Leo Pharma A/S Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases
CN102781425A (zh) * 2009-12-22 2012-11-14 利奥制药有限公司 含有维生素d类似物以及溶剂和表面活性剂混合物的皮肤用组合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
维生素D治疗肾性骨病以外的作用;无;《飞华健康网http://zzk.fh21.com.cn/article/detail/102411.html》;20091220;倒数第2段 *

Also Published As

Publication number Publication date
US20150297616A1 (en) 2015-10-22
WO2014083099A1 (en) 2014-06-05
CN104822392A (zh) 2015-08-05
EP2925364A1 (en) 2015-10-07
JP6367819B2 (ja) 2018-08-01
RU2663448C2 (ru) 2018-08-06
JP2016501209A (ja) 2016-01-18
US9855285B2 (en) 2018-01-02
RU2015125680A (ru) 2017-01-10
HK1212894A1 (zh) 2016-06-24

Similar Documents

Publication Publication Date Title
US9855285B2 (en) Method of inhibiting the expression of IL-22 in activated T-cells
Lee et al. Effects of 13-alkyl-substituted berberine alkaloids on the expression of COX-II, TNF-α, iNOS, and IL-12 production in LPS-stimulated macrophages
Yoon et al. Anti-inflammatory effect of quercetin in a whole orbital tissue culture of Graves' orbitopathy
Izeboud et al. The β-adrenoceptor agonist clenbuterol is a potent inhibitor of the LPS-induced production of TNF-α and IL-6 in vitro and in vivo
Wedel et al. SAFit2 reduces neuroinflammation and ameliorates nerve injury-induced neuropathic pain
Profita et al. Smoke, choline acetyltransferase, muscarinic receptors, and fibroblast proliferation in chronic obstructive pulmonary disease
JP2013538803A (ja) 心血管疾患を治療するための組成物および方法
JP2013533320A (ja) タウオパチーを治療するための組成物および方法
EP3145513B1 (en) 3-(4-((4-(morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus
JP2015527349A (ja) 免疫関連及び炎症性疾患の治療
Liang et al. Small extracellular vesicles from hypoxia-preconditioned bone marrow mesenchymal stem cells attenuate spinal cord injury via miR-146a-5p-mediated regulation of macrophage polarization
JP2023524290A (ja) Ｓａｒｓ－ｃｏｖ－２の治療のための方法及び組成物
JP5941908B2 (ja) 神経毒性剤からの保護方法および組成物
US20100004244A1 (en) Use of cb2 receptor agonists for promoting neurogenesis
JP2009520697A (ja) サイトカイン調節性を有する化合物
Draheim et al. Anti-inflammatory potential of the selective phosphodiesterase 4 inhibitor N-(3, 5-dichloro-pyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), in human cell preparations
TW202207921A (zh) 以二甲基胺基吖呾醯胺化合物治療受冠狀病毒感染的患者之方法
US20220119765A1 (en) Differentiation method of neural stem cells manufactured by direct cell conversion into astrocytes
Mahmutovic-Persson et al. Capacity of capsazepinoids to relax human small airways and inhibit TLR3-induced TSLP and IFNβ production in diseased bronchial epithelial cells
HK1212894B (en) A method of inhibiting the expression of il-22 in activated t-cells
JP2022524911A (ja) 皮膚創傷治癒不全を治療するための選択的グルココルチコイド受容体モジュレーター
KR20170044203A (ko) 이중 pi3k 델타-감마 키나제 억제제 및 코르티코스테로이드를 포함하는 조성물 및 치료방법
JP2009215284A (ja) ゲラニルゲラニル化阻害による制御性ｔ細胞の分化誘導およびその治療応用
Matsuo et al. 15d-PGJ2 inhibits oxidized LDL-induced macrophage proliferation by inhibition of GM-CSF production via inactivation of NF-κB
Guo et al. A transdermal drug delivery system based on estradiol liposomes enhances the alleviation of psoriatic skin inflammation

Legal Events

Date Code Title Description
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1212894

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1212894

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170908

Termination date: 20191128